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Background. In addition to the human coronaviruses (HCoVs) OC43 and 229E, which have been known for
decades to cause infection in humans, 2 new members of this genus have recently been identified: HCoVs NL63
and HKU1. Their impact as a cause of respiratory tract disease in adults at risk for complications needs to be
established.
Methods. We prospectively assessed the clinical impact of coronavirus infection (excluding cases of severe
acute respiratory syndrome) among hospitalized adults. All patients with respiratory disease for whom bron-
choalveolar lavage was performed were screened by reverse-transcriptase polymerase chain reaction for the presence
of all 4 HCoVs.
Results. HCoV was identified in 29 (5.4%) of 540 bronchoalveolar lavage fluid specimens from 279 subjects
(mean age, 51 years; 63% male). HCoV OC43 was identified most frequently (12 isolates), followed by 229E (7
isolates), NL63 (6 isolates), and HKU1 (4 isolates). In all, 372 (69%) of 540 bronchoalveolar lavage fluid specimens
were negative for bacteria, and 2 persons were coinfected with other respiratory viruses. Transplantation was the
most common underlying condition. Of the 29 patients who had HCoV identified in their bronchoalveolar lavage
fluid specimens, 9 (31%) were hospitalized in the intensive care unit, 22 (76%) presented to the hospital with
acute respiratory symptoms, 16 (55%) presented with cough and/or sputum, 13 (45%) presented with dyspnea,
16 (55%) had experienced prior respiratory infection, and 18 (62%) had a new infiltrate that was visible on chest
radiograph. The most frequent final diagnosis was a lower respiratory tract infection.
Conclusions. The recently discovered HCoVs NL63 and HKU1 contribute significantly to the overall spectrum
of coronavirus infection. Our study also suggests that coronaviruses contribute to respiratory symptoms in most
cases.
Human coronaviruses (HCoVs) are recognized as one
of the most frequent causes of common colds and upper
respiratory tract infections, after rhinoviruses, in adults
[1]. In immunocompetent adults, most of these ill-
nesses are self-limiting; however, recent evidence sug-
gests that these viruses are also associated with lower
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respiratory tract symptoms and protracted disease in
subjects at risk for complications [2, 3]. Indeed, HCoVs
have been recovered from the lower respiratory tract
specimens of patients with pneumonia, young infants,
and immunocompromised persons with lower respi-
ratory tract complications [4]. However, most studies
investigating the clinical impact of coronavirus infec-
tion have been limited by their retrospective design or
by the study population. Another unexpected limitation
has been the number of different HCoVs analyzed [5].
Until recently, only HCoV 229E and HCoV OC43 were
known to infect humans; however, since the identifi-
cation of the severe acute respiratory syndrome
(SARS)–associated coronavirus (not considered in this
study), 2 new coronaviruses have been identified:
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HCoV NL63 was identified in 2004 [6], and HCoV HKU1 was
identified in 2005 [7, 8]. Several studies from different parts
of the world have now established that HCoV NL63 can be
recovered from a substantial number of respiratory specimens,
mainly from specimens from children with respiratory symp-
toms [9–12] and, less frequently, from specimens from adults
with respiratory symptoms [13, 14]. HCoV HKU1 was origi-
nally identified in a specimen obtained from an elderly man
with pneumonia in Hong Kong [8]. Recent studies suggest that
this virus might be distributed worldwide [15], although the
reported number of cases of infection remains very limited.
Few studies have attempted to prospectively establish the clin-
ical impact of all 4 HCoVs as causes of infection in hospitalized
adult patients and to describe the associated clinical features
and the potential respiratory complications. In the present pro-
spective study, we first systematically analyzed the presence of
all 4 HCoVs in patients who required bronchoalveolar lavage
(BAL) for an acute respiratory event and then analyzed the
associated clinical conditions and outcome of infection.
METHODS
In the present investigation, patients were enrolled in a hospital-
based, prospective cohort study. All patients who underwent
BAL were eligible, irrespective of the reason leading to the
procedure. For lung transplant recipients, the study was con-
ducted at the 2 sites of our transplantation network, the Uni-
versity Hospitals of Geneva (Geneva, Switzerland) and the Uni-
versity Hospital of Lausanne (Lausanne, Switzerland). BAL was
performed according to our guidelines for the following pa-
tients: immunocompromised patients who had persistent in-
filtrates visible on chest radiograph, despite large-spectrum an-
tibiotic treatment; HIV-infected patients who had low CD4+
cell counts and interstitial infiltrates or suspected pulmonary
opportunistic infections; patients with suspected pulmonary
tuberculosis whose sputum analysis had negative findings; pa-
tients with persistent, diffuse interstitial infiltrates of unknown
origin; and exacerbation of symptoms in patients with chronic
interstitial diseases or nosocomial pneumonia who had exac-
erbation of symptoms (including patients who were intubated
and treated with wide-spectrum antibiotics without response
and who had tumor-like abnormalities). In lung transplant
recipients, BAL was also performed as a follow-up or diagnostic
procedure, either following transplantation when organ rejec-
tion is suspected or after antirejection treatment; thus, lung
transplant recipients could have several BALs performed during
the follow-up period. Patients were considered to be immu-
nosuppressed when they were receiving treatment with anti-
rejection drugs, were receiving chemotherapy (regardless of
neutropenia), were receiving steroids (10 mg per day) for at
least 1 week before the BAL procedure, or were HIV infected
with a CD4+ cell count !200 cells/mm3.
BAL fluid specimens from all patients were screened by RT-
PCR for the presence of the 4 coronaviruses known to infect
humans (HCoV OC43, HCoV 229E, HCoV NL63, and HCoV
HKU1), as well as 10 additional respiratory viruses (influenza
A and B viruses; respiratory syncytial viruses A and B; human
parainfluenza viruses 1, 2, and 3; human rhinovirus; entero-
virus; and human metapneumovirus). Presence of Mycoplasma
pneumoniae, Chlamydophila pneumoniae, and Legionella
pneumophila was also determined by PCR.
Shortly before the BAL procedure was performed, a baseline
case report form was completed by a physician who was blinded
to any microbiological test results. The information recorded
included underlying diseases, presence of fever, type and du-
ration of respiratory symptoms, response to any antimicrobial
and/or antiviral therapy, reason(s) for the BAL procedure, and
the presumed diagnosis (determined on the basis of the avail-
able evidence at the time). Three days after the BAL procedure,
a follow-up case report form was completed to assess symptom
evolution, response to treatment, new chest radiography find-
ings (if available), and results of microbiological tests. Follow-
up at 30 days was performed to assess the outcome and final
diagnosis and to record data from any additional microbio-
logical tests and/or pathological examinations, if available. For
patients included in this particular analysis of coronavirus in-
fection, we also performed an additional review of all medical
files available to collect any additional information on the de-
scription, evolution, and cause of clinical symptoms.
BAL was performed in accordance with standardized pro-
tocol: 30–50 mL of sterile saline solution were instilled 2–4
times into the distal bronchial tree, either at the radiographic
site of the chest abnormality or in the middle lobe. All BAL
fluid specimens were initially pooled and then separated into
aliquots and processed similarly for subsequent analysis. Gram,
acridine orange, Truant auramine-rhodamine, and Giemsa
staining were performed for direct identification of bacteria,
mycobacteria, fungi, and parasites, respectively. Cultures for
bacterial identification were inoculated under standard aerobic
conditions onto 4 different media, as well as onto specific media
for mycobacterium detection, when indicated by the clinical
conditions. Pulmonary bacterial infection was considered to be
proven when quantitative culture for a given bacteria yielded
1103 colony-forming units per mL of specimen, in association
with clinical and radiological symptoms; if these conditions
were not met, the culture was considered to indicate
colonization.
BAL fluid specimens were inoculated on 4 different cell lines
for viral detection (human embryonic fibroblasts and A549,
MDCK, and LLC-MK2 cells). An aliquot was immediately fro-
zen at 80C and used for duplicate RT-PCR and PCR assays.
Real-time TaqMan RT-PCR assays for the detection of influenza
A and B viruses, respiratory syncytial viruses A and B, human
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Table 1. Baseline characteristics and comorbidities of patients
with human coronavirus (HCoV) infection.
Characteristic
Patients with
HCoV infection
(n p 29)
Age, mean years (range) 46.6 (13–77)
Male sex 20 (69)
Comorbid condition
Solid-organ transplant
Any 14 (48)
Lunga 12
Heart 1
Kidney 1
Solid organ or hematopoietic cancer 4 (14)
HIV infection 3 (10)
Autoimmune disease 3 (10)
Other 5 (17)
Immunosuppressive therapy,b
Any 4 (14)
Steroids 3
Chemotherapy 2
Methotrexate 1
Hospitalized at time of bronchoalveolar lavage
Overall 27 (93)
Medical ward 18
Intensive care unit 9
Received ambulatory care 2 (7)
Antibiotic therapy at time of BAL
Any 22 (76)
For treatment of suspected bacterial infection 16
For prophylaxis only 10
For tuberculosis 2
No antibiotic therapy at time of BAL 7 (24)
NOTE. Data are no. (%) of patients, unless otherwise indicated.
a Two lung transplantation recipients also had a concomitant liver
transplant.
b Therapy for patients who did not undergo transplantation.
parainfluenza viruses 1, 2, and 3, human rhinovirus, entero-
virus, and human metapneumovirus were performed as de-
scribed elsewhere [16, 17]. In brief, RNA was extracted from
200 mL of each BAL fluid specimen (HCV Amplicor Specimen
Preparation Kit; Roche Diagnostics), and retrotranscription was
performed using the SuperscriptTM II RNase H–Reverse Tran-
scriptase (Invitrogen Life Technologies) and the random primer
pd(N)6 (Roche Diagnostics GmbH). Amplification and detec-
tion were performed using an ABI Prism 7900 HT (Applied
Biosystems). All of the different steps of the extraction and
retrotranscription were conducted in parallel with a known
positive supernatant of human rhinovirus 2–infected cells and
appropriate negative controls.
The forward primers, reverse primers, and probes that were
used for the detection of coronaviruses are described elsewhere
[17]. We completed the analysis with an RT-PCR targeting
HCoV HKU1 using similar PCR conditions. As a control for
this assay, we used a 506–base pair PCR product (GenBank
accession number AY59704). The forward primer was 5′-GAA
TTT TGT TGT TCA CAT GGT GAT AGA-3′, the reverse primer
used was 5′-GCA ACC GCC ACA CAT AAC TAT TT-3′, and
the probe was 5′-FAM TTT ATC GCC TTG CGA ATG AAT
GTG CTC TAMRA-3′. Validation experiments using the above-
mentioned PCR product as our PCR target showed that the
analytical sensitivity of our PCR assay was !18 copies/mL.
This study was approved by the ethics committees of Uni-
versity Hospitals of Geneva (Geneva, Switzerland) and the Uni-
versity Hospital of Lausanne (Lausanne, Switzerland). In-
formed, signed consent forms were obtained from all
participants.
RESULTS
During a 20-month period, we analyzed 540 BAL fluid speci-
mens obtained from 279 patients who were enrolled in the
study (median length of enrollment, 1 month; range, 1–20
months). The mean age was 51 years, and 177 patients (63.4%)
were male. Among all BAL fluid specimens that were examined,
307 (57%) of 540 were from lung transplant recipients, 39
(14%) of 279 were from patients treated with immunosup-
pressive therapy, 19 (7%) of 279 were from HIV-infected pa-
tients, and 8 (3%) of 279 were from patients with other im-
munosuppressive conditions. HCoV was identified in 29 (5.4%)
of 540 BAL fluid specimens, whereas 57 (11%) of 511 BAL
fluid specimens that had results negative for HCoV had results
positive for other respiratory viruses. Overall, 86 (16%) of 540
specimens had test results positive for any respiratory virus.
Among HCoV-positive specimens, HCoV OC43 was the most
frequent species isolated (12 [41.4%] of 29 specimens), fol-
lowed by 229E (7 [24.1%] of 29 specimens), NL63 (6 [20.7%]
of 29 specimens), and HKU1 (4 [13.8%] of 29 specimens). The
median age of the patients from which the HCoV-positive spec-
imens were obtained was 46.6 years (range, 13–77 years), and
20 (69%) of 29 were male. Transplantation was the most fre-
quent underlying condition; 12 patients (49%) were lung trans-
plant recipients, and 2 (16.7%) of those 12 also received a liver
transplant. Only 8 (28%) of 29 patients were not considered
to be immunosuppressed. Other baseline characteristics and
comorbidities are described in table 1. BAL was performed for
only 2 (0.7%) of 279 ambulatory patients; all others (277
[99.3%]) were hospitalized for a median duration of 48 days
(range, 2–245 days). At the time of the procedure, 22 (76%)
of the 29 patients had received antibiotic treatment. Nine (31%)
of the 29 patients were hospitalized in the intensive care unit
at the time of the BAL procedure (of these, 8 were receiving
mechanical ventilation). The reasons leading to the perfor-
mance of the BAL procedure are given in table 2.
At the time of BAL, acute respiratory symptoms and/or new
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Table 2. Condition and/or the presumed diagnosis leading to
performance of bronchoalveolar lavage for 29 patients with hu-
man coronavirus infection.
Condition or presumed diagnosis
Patients,
no. (%)
Patients who did not receive a lung transplant (n p 17)
Suspected lower respiratory tract infection
Any 17 (100)
Pneumonia 13
Opportunistic lower respiratory tract infection 5
Exacerbation of respiratory symptoms in the pres-
ence of a known lung conditiona 4 (24)
Patients who received a lung transplant (n p 12)
Suspected lower respiratory tract infection 8 (67)
Suspected rejection 6 (50)
Follow-up after rejection treatment 2 (17)
Follow-up after transplantation 1 (8)
NOTE. For some patients, there may have been 11 reason leading to the
performance of bronchoalveolar lavage.
a These conditions were tracheal stenosis, pulmonary contusion,pulmonary
fibrosis, and bronchopleural fistula.
Table 3. Final diagnosis received by 29 patients with human
coronavirus infection.
Diagnosis
Patients,
no. (%)
Patients who did not receive a lung transplant (n p 17)
Lower respiratory tract infection
Any 12 (71)
Bacterial 3
Pseudomonas aeruginosa infection 1
Escherichia coli infection 1
Staphylococcus aureus infection 1
Fungal 3
Pneumocystis jirovecii infection 2
Aspergillosis infection 1
Unspecified diagnosis 6
Tuberculosis 1 (6)
Exacerbation of respiratory symptoms in the pres-
ence of a previous lung condition 4 (24)
Patients who did not receive a lung transplant (n p 12)
Lower respiratory tract infection
Any 4 (33)
Pneumoniaa 2
Empyema 2
Respiratory symptoms or abnormal lung function of
unspecified etiology 7 (58)
Rejection episodeb 3 (25)
Bronchiolitis obliterans syndrome 1 (8)
NOTE. Some patients may have received 11 diagnosis.
a Pneumonia due to P. aeruginosa or Stenotrophomonas maltophilia.
b Degree of rejection, as defined by the International Society of Heart and
Lung Transplantation: A3/B2, A4/B1, A1/BO.
chest abnormalities visible on radiograph were present in all
patients with HCoV infection. Of the 29 patients, 22 (76%)
presented with acute respiratory symptoms, 16 (55%) presented
with cough and/or sputum, and 13 (45%) presented with dysp-
nea. New abnormalities visible on chest radiograph were doc-
umented in 18 patients (62%). Abnormalities included inter-
stitial infiltrates (10 patients [55.6%]), alveolar or localized
infiltrates (5 [27.8%]), pleural effusions (2 [11.1%]), and pneu-
mothorax (1 [5.6%]). The mean cell count in the BAL fluid
specimens was cells/mL (range, 4– cells/mL),4 424 10 102 10
with 18.3% neutrophils (range, 1%–71%) and 14.4% lympho-
cytes (range, 2%–37%).
Sixteen patients (55%) were already receiving treatment for
a respiratory infection at the time of BAL, and in 12 patients
(41%), antibiotic therapy was modified during the follow-up
period. In 7 other patients (24%), antibiotic therapy was started
immediately following BAL. Most patients (52%) received a
diagnosis of acute lower respiratory tract infection at hospital
discharge (table 3).
In 20 patients (69%), the microbiological test results of the
BAL specimens were negative for typical bacteria (tested for by
standard culture) and atypical bacteria (tested for by PCR), as
well as for other respiratory viruses and herpesviruses. Of note,
15 (75%) of these patients were receiving antibiotic treatment
at the time that they provided BAL fluid specimens.
In the remaining 9 patients (31%), microbiological test re-
sults were positive for typical or atypical bacteria or other re-
spiratory viruses or herpesviruses, and 5 (55.6%) of these pa-
tients were receiving antibiotic treatment (OR, 0.412; 95% CI,
0.0793–2.190). A bacterium likely to be a cause of infection
was isolated from samples obtained from 5 patients, and 2
patients received a diagnosis of Pneumocystis jirovecii pneu-
monia. Herpes simplex virus and cytomegalovirus were isolated
from samples from 1 patient each but were not considered to
be the cause of the respiratory symptoms. Screening for other
respiratory viruses had positive results in 2 patients, 1 of whom
was coinfected with human rhinovirus and 1 of whom had
respiratory syncytial virus coinfeciton.
For 3 (10.3%) of 29 patients, the 30-day outcome was not
available: 1 patient (3.4%) was lost to follow-up, and 2 (6.9%)
were transferred to hospitals outside Switzerland on days 9 and
12, respectively. The overall mortality rate at day 30 was 10%
(3 deaths). Two patients with chronic pulmonary disease (pul-
monary fibrosis and lung cancer) died of respiratory failure on
days 2 and 10, respectively, and 1 patient died of heart failure
on day 30. One of these patients was infected with HCoV 229E,
and 2 were infected with HCoV OC43.
We had the opportunity to analyze 34 BAL fluid specimens
obtained from 10 (34.5%) of the 29 patients with HCoV in-
fection (9 of whom were lung transplant recipients) after the
patients were known to have HCoV infection (median of 3
HCoV Infection in Hospitalized Patients • CID 2006:43 (15 October) • 1013
BAL fluid specimens per patient; range, 1–10 specimens), with
a median follow-up duration of 32 weeks (range, 15–65 weeks).
The screening for all 4 coronaviruses had negative results in
all but 1 patient. This patient had HIV infection (CD4+ cell
count, 80 cells/mm3) and developed P. jirovecii pneumonia with
persistent abnormalities visible on chest radiographs, despite 3
weeks of treatment with sulfamethoxazole. Results of cultures
of BAL fluid samples obtained after 3 weeks were still positive
for HCoV OC43.
Of the 540 BAL procedures conducted, 303 (56%) were per-
formed during the cold season (autumn and winter), and 237
(44%) were performed during the rest of the year. The seasonal
distribution for cases of HCoV infection was significantly
higher during the cold season (20 cases [67%]), compared with
the rest of the year (9 cases [31%]; ).Pp .01
DISCUSSION
We analyzed the results of all cultures of BAL fluid specimens
obtained from patients with acute respiratory tract illnesses in
a prospective, hospital-based cohort of adult patients. Of the
540 specimens analyzed, we identified 29 (5.4%) that dem-
onstrated HCoV infection. Interestingly, all 4 species of HCoV
were present: the classic OC43 and 229E types comprised 65%
of isolates, and the new NL63 and HKU1 types comprised 35%.
Infections due to NL63 and HKU1 illustrate the potential role
and impact of these newly discovered virus types and highlight
the need to continuously adapt diagnostic tools to new species.
In most cases of illness, the presence of clinical signs or ab-
normalities visible on chest radiographs (mainly interstitial in-
filtrates) that were compatible with a diagnosis of acute viral
respiratory tract infection prompted the performance of BAL.
Antibiotics given to patients before performance of BAL had
a limited effect, and clinical failure prompted a switch of an-
tibiotic treatment in 140% of patients. In addition, HCoV was
the only infectious agent identified in most cases; the results
of all other microbiological testing were negative. Similarly,
bacteriological test results were also negative in 45% of patients
who were not treated with antibiotics before they underwent
BAL, which suggests that, in these patients, HCoV infection
was the leading cause of symptoms that led to performance of
BAL. Serious associated comorbidities and/or immunocom-
promised conditions that could promote lower respiratory viral
complications were also present in all patients. Finally, the study
design provided the opportunity to analyze additional BAL
samples obtained before and/or after illness due to HCoV in-
fection in 10 (34.5%) of the 29 enrolled patients. All but 1
sample were negative for coronavirus, which demonstrates that
the virus was present during the acute phase of respiratory
symptoms that led to BAL and was not asymptomatic colo-
nization. These observations strongly suggest that, in a sub-
stantial number of our patients, HCoV played a role in and/
or promoted the lower respiratory diseases observed.
Coronaviruses have been shown to be associated with lower
respiratory tract complications, but such complications mostly
affect children. To our knowledge, no study has either pro-
spectively analyzed a large number of adult patients or analyzed
all 4 HCoVs as causes of infection in patients at high risk of
complications. One study, performed retrospectively and in-
volving bone marrow transplant recipients, failed to detect
HCoV in stored BAL fluid specimens [18]. This difference with
our results might be explained by several factors. Our patients
were selected only on the basis of the need for BAL—not on
the basis of predefined clinical criteria. We did not focus on
selected subgroups of patients, 2 winter seasons were covered,
and sensitive, real-time RT-PCR assays targeting the 4 HCoVs
were performed. The prospective design of our investigation
has, therefore, avoided many of the limitations observed in
retrospective studies and gives an estimate of the impact of
coronaviruses among patients hospitalized with serious chronic
and/or immunosuppressive conditions.
Since the first well-defined cases of HCoV infection were
documented [6, 7], the incidence of infection due to and the
respective roles of HCoV NL63 and HCoV HKU1 among an
adult population have not been assessed in a systematic manner.
HCoV NL63 and similar viruses [25, 26], as causes of respi-
ratory disease, have been studied mostly in retrospective series
or in analyses of stored specimens collected from children [12].
In these large series, the prevalence of HCoV NL63 infection
ranged from 2.2% to 9.3% [10, 11, 13, 14, 19–21]. One of the
largest studies [14] retrospectively tested 840 nasopharyngeal
aspirates in a hospital-based pediatric population with acute
respiratory disease and found 16 children with HCoV NL63
infection. Most of these children presented with lower respi-
ratory tract symptoms requiring hospitalization. Another study
[25] of 1265 specimens from 895 children with symptoms of
lower and/or upper respiratory infection identified 79 speci-
mens positive for HCoV (designated New Haven) that is closely
related to NL63. Most children presented with infiltrates visible
on chest radiographs, and a substantial number of these chil-
dren were hospitalized in critical condition. Taken together,
these data strongly suggest an association between HCoV NL63
and lower respiratory tract diseases in children. Since its first
description in an elderly man with pneumonia [7], 2 other
adults cases of infection due to HCoV HKU1 have been re-
ported among a rescreened population [8, 22], and 2 cases were
diagnosed by screening respiratory samples sent for viral anal-
ysis [15, 23]. In another study, by Woo et al. [24], conducted
during the SARS outbreak in Hong Kong, nasopharyngeal as-
pirates were collected from 418 patients with community-ac-
quired pneumonia (all of whom had abnormalities visible on
chest radiographs) who were subsequently screened for HKU1.
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Woo and colleagues found 10 cases of HCoV infection, 9 of
which occurred in adults. A review of patient medical charts
showed that approximately one-half of the patients had chronic
lung disease. Hospitalization was required for most patients,
and 2 patients died. Our findings are consistent with those of
these previous investigations; we demonstrate that HCoV NL63
and HKU1 can also be detected in lower respiratory tract spec-
imens obtained from adults and provide a comparison of their
respective roles in causing illness. During the 2 seasons during
which our study was conducted, NL63 and HKU1 were less
frequently identified than the classic OC43 and 229E species,
but they nevertheless contributed significantly to the overall
spectrum of coronavirus-associated diseases among hospital-
ized adult patients.
A large subgroup of patients that emerged in our analysis is
lung transplant recipients. Recent reports regarding this pop-
ulation have suggested a link between viral respiratory tract
infections and graft dysfunction or bronchiolitis obliterans syn-
drome [27–33]. However, in these studies, coronaviruses were
not investigated because of the need to use in-house and up-
dated PCR assays. For most of our patients, the main final
diagnosis was a lower respiratory tract infection and/or acute
respiratory symptoms of unspecified etiology, despite extensive
routine investigations. This supports the hypothesis that co-
ronavirus infection promoted the lower respiratory tract disease
observed in these patients.
In conclusion, in the present prospective study, we provide
a comprehensive analysis of the potential impact of all 4 HCoVs
as causes of infection among hospital-based patients. Overall,
coronaviruses were recovered in 5.4% of all BAL fluid speci-
mens analyzed, and HCoV infection was most commonly ob-
served in patients at high risk of respiratory complications,
including lung transplant recipients. The recently discovered
species HCoV NL63 and HCoV HKU1 contributed significantly
to the spectrum of HCoV-associated disease in our study.
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